Nexus NeuroTech

Established in 2023, Nexus NeuroTech focuses on accelerating innovations in brain disorder technologies. The company invests in and develops medical devices, software, diagnostics, care services, and research instruments to advance treatments and improve patient outcomes.

William J. Marks

CMO, General Partner and Co-Founder

Jordi Parramon

CEO, General Partner and Co-Founder

6 past transactions

Nobi

Series B in 2025
Nobi is a smart lamp that ensures help can be provided in a flash in the event of a fall. It recognizes a fall, and it will notify a family member, contacts, or a specialized emergency call center. The lamp will then connect to that person to reassure them that help is on the way. If necessary, it can even unlock the smart lock on the front door.

Cala Health

Series C in 2024
Cala Health is a bioelectronic medicine company that develops wearable neuromodulation therapies for chronic diseases. Its primary product, Cala Trio therapy, is a non-invasive prescription treatment for essential tremor.

Cortica

Venture Round in 2024
Cortica Inc. is a company dedicated to providing neurological therapies for children facing autism and other neurodevelopmental challenges. Founded in 2014 and based in San Diego, California, Cortica offers tailored treatment programs that are informed by a comprehensive understanding of each child's neurobiology and developmental profile. The company operates multiple centers across California, including locations in Carlsbad, Irvine, San Rafael, Torrance, and Westlake Village. Cortica's services encompass a wide range of assessments and therapies, including diagnoses for autism, ADHD, and developmental delays. Treatment options available include gene sequencing, metabolic testing, electroencephalography, nutrition evaluation, medication management, and various therapeutic interventions such as ABA therapy, parent coaching, speech-language therapy, occupational therapy, physical therapy, and music therapy. The company provides these services through in-home, in-clinic, and telehealth modalities.

Synapticure

Series A in 2024
Synapticure specializes in providing remote, disease-specific neurological care for patients with neurodegenerative diseases such as dementia, Parkinson's, and ALS across the United States. Founded by patients, they offer on-demand neurologists, speech-language therapists, round-the-clock care coordination, and support services tailored to each patient's needs.

EarliTec Diagnostics

Series B in 2024
EarliTec Diagnostics is a digital health company developing innovative diagnostic tools for autism spectrum disorder (ASD) and related disabilities in children. Founded by renowned researchers from Children’s Healthcare of Atlanta, Emory University School of Medicine, and Yale University, EarliTec aims to enable earlier identification and treatment through its proprietary technology that quantifies social-visual engagement.

Rune Labs

Venture Round in 2024
Founded in 2018, Rune Labs develops a SaaS platform that integrates with neuromodulation systems to manage complex therapies. It processes brain imaging and electrophysiology data for neuroscience therapeutics, serving pharmaceutical companies to deliver precision therapies for conditions like Parkinson's disease, epilepsy, depression, and OCD.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.